

Accepted Manuscript



Lack of Benefit from the Addition of External Beam Radiotherapy to Brachytherapy for Intermediate- and High-Risk Prostate Cancer

David D. Yang, BA, Vinayak Muralidhar, MD, MSc, Paul L. Nguyen, MD, Ivan Buzurovic, PhD, Neil E. Martin, MD, MPH, Kent W. Mouw, MD, PhD, Phillip M. Devlin, MD, Quoc-Dien Trinh, MD, Peter F. Orio, III, DO, MS, Martin T. King, MD, PhD

PII: S0360-3016(17)33622-2

DOI: [10.1016/j.ijrobp.2017.07.034](https://doi.org/10.1016/j.ijrobp.2017.07.034)

Reference: ROB 24434

To appear in: *International Journal of Radiation Oncology • Biology • Physics*

Received Date: 19 May 2017

Revised Date: 11 July 2017

Accepted Date: 24 July 2017

Please cite this article as: Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh Q-D, Orio III PF, King MT, Lack of Benefit from the Addition of External Beam Radiotherapy to Brachytherapy for Intermediate- and High-Risk Prostate Cancer, *International Journal of Radiation Oncology • Biology • Physics* (2017), doi: 10.1016/j.ijrobp.2017.07.034.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Lack of Benefit from the Addition of External Beam Radiotherapy to Brachytherapy for Intermediate- and High-Risk Prostate Cancer

Short title: Brachytherapy for intermediate- and high-risk prostate cancer

Authors: David D. Yang, BA^{1,*}; Vinayak Muralidhar, MD, MSc^{2,*}; Paul L. Nguyen, MD^{1,3}; Ivan Buzurovic, PhD^{1,3}; Neil E. Martin, MD, MPH^{1,3}; Kent W. Mouw, MD, PhD^{1,3}; Phillip M. Devlin, MD^{1,3}; Quoc-Dien Trinh, MD^{1,4}; Peter F. Orio, III, DO, MS^{1,3,**}; Martin T. King, MD, PhD^{1,3,**}

* Co-first authors

** Co-senior authors

Affiliations

¹Harvard Medical School, Boston, MA, USA

²Harvard Radiation Oncology Program, Boston, MA, USA

³Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

⁴Division of Urological Surgery, Brigham and Women's Hospital, Boston, MA, USA

Statistical analysis

David D. Yang, BA

Address: Department of Radiation Oncology, 75 Francis St, ASBI-L2, Boston, MA 02115

Telephone: (203) 802-8327

Fax: (617) 975-0912

Email: david_yang@hms.harvard.edu

Vinayak Muralidhar, MD, MSc

Address: Department of Radiation Oncology, 75 Francis St, ASBI-L2, Boston, MA 02115

Telephone: (617) 732-7936

Fax: (617) 975-0912

Email: vmuralidhar@partners.org

Corresponding author

Martin T. King, MD, PhD

Address: Department of Radiation Oncology, 75 Francis St, ASBI-L2, Boston, MA 02115

Telephone: (617) 278-6988

Fax: (617) 732-4332

Email: Martin_King@dfci.harvard.edu

Conflicts of interest

- P.L.N. has consulted for Ferring Pharmaceuticals, Medivation, GenomeDx Biosciences, Dendreon, and Nanobiotix and received research support for clinical trials from Astellas Pharma and Janssen Pharmaceuticals, unrelated to this submitted work.
- N.E.M. has received financial compensation for being a committee chair of Via Oncology, unrelated to this submitted work.

Download English Version:

<https://daneshyari.com/en/article/5498056>

Download Persian Version:

<https://daneshyari.com/article/5498056>

[Daneshyari.com](https://daneshyari.com)